Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of WVL909 in healthy volunteers
jRCT2071260083Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of WVL909 (4 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
WVL909
Beyond the preview
Go deeper on jRCT2071260083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260083.